---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-159026"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2025-07-15T23:59:59+00:00"
generated_at: "2026-05-18T06:26:11.217571+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neuronetics appoints Steven Pfanstiel as CFO; reaffirms Q2 & FY2025 guidance

## Summary
- Pfanstiel named CFO effective July 15, replacing retiring Steve Furlong (through March 2026).
- Pfanstiel previously CFO/COO of Marinus Pharmaceuticals; 20+ years medical device/pharma experience.
- Inducement grant of 400,000 RSUs vesting over 3-4 years; base salary $480k, 50% target bonus.
- Reaffirms Q2 and full-year 2025 guidance; targets positive cash flow in Q3 2025.
- Outgoing CFO Furlong remains as Senior Advisor to CEO through end of March 2026.

## SEC filing metadata
- accession: 0001193125-25-159026
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2025-07-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000119312525159026/0001193125-25-159026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000119312525159026/d34717d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-159026
- JSON: https://secwatch.observer/filing/0001193125-25-159026.json
- Plain text: https://secwatch.observer/filing/0001193125-25-159026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.